TGFB1 and hepatocellular carcinoma: Mazzocca et al. [26] found that transforming growth factor-β (TGF-β) receptor inhibitor LY2109761 could inhibit production of TGF-β secreted by CAFs, and block the cross-talk between CAFs and HCC, and thus inhibit the progression of HCC.